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Abstract
Background: The aim of this study was to project health-economic outcomes relevant to the
German setting for the addition of pioglitazone to existing treatment regimens in patients with type
2 diabetes, evidence of macrovascular disease and at high risk of cardiovascular events.
Methods:  Event rates corresponding to macrovascular outcomes from the Prospective
Pioglitazone Clinical Trial in Macrovascular Events (PROactive) study of pioglitazone were used
with a modified version of the CORE Diabetes Model to simulate outcomes over a 35-year time
horizon. Direct medical costs were accounted from a healthcare payer perspective in year 2005
values. Germany specific costs were applied for patient treatment, hospitalization and management.
Both costs and clinical benefits were discounted at 5.0% per annum.
Results: Over patient lifetimes pioglitazone treatment improved undiscounted life expectancy by
0.406 years and improved quality-adjusted life expectancy by 0.120 quality-adjusted life years
(QALYs) compared to placebo. Direct medical costs (treatment plus complication costs) were
marginally higher for pioglitazone treatment and calculation of the incremental cost-effectiveness
ratio (ICER) produced a value of €13,294 per QALY gained with the pioglitazone regimen versus
placebo. Acceptability curve analysis showed that there was a 78.2% likelihood that pioglitazone
would be considered cost-effective in Germany, using a "good value for money" threshold of
€50,000 per QALY gained. Sensitivity analyses showed that the results were most sensitive to
changes in the simulation time horizon. After adjustment for the potential stabilization of pancreatic
β-cell function with pioglitazone treatment, the ICER was €6,667 per QALY gained for pioglitazone
versus placebo.
Conclusion: The findings of this modelling analysis indicated that, for patients with a history of
macrovascular disease, addition of pioglitazone to existing therapy reduces the long-term
cumulative incidence of diabetes-complications at a cost that would be considered to represent
good value for money in the German setting.
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Introduction
The direct cost of care for patients with diabetes accounts
for 14.2% of total health care costs in Germany, and as the
number of diagnosed type 2 diabetes patients continues
to rise this is likely to increase substantially in the future
[1]. However the cost of diabetes in Germany is not evenly
distributed, with approximately 15% of patients being
responsible for almost 60% of all direct costs and the pres-
ence of diabetes-related complications being the most
important driver of increasing costs [1,2]. Targeting of
resources to these cost-intensive patients with, or at high
risk for, complications may represent a more pragmatic
and effective strategy on which to base healthcare policy
aimed at containing the current escalation in diabetes-
related costs in Germany [1,3].
Based on data relating to 809 patients, the German arm of
the Cost of Diabetes in Europe-type 2 (CODE-2) con-
ducted in 1998 identified complications as the greatest
contributor to direct costs of diabetes care [4]. In CODE-
2, relative to no complications the presence of either
microvascular or macrovascular complications increased
direct costs by two-fold whilst for patients with both
microvascular and macrovascular complications costs
were increased by four-fold. Similarly in the more recent
German Cost of Diabetes Mellitus (CoDiM) study of
26,971 diabetes patients insured by a large health insur-
ance fund (AOK-Hessen) between 1998 and 2002, the
mean annual cost per patient with at least one complica-
tion was 2.5-fold higher compared to those without com-
plications (€6,766 versus €2,756) [3]. Corresponding
values for patients with two or three complications versus
those without complications were a 2.9 fold (€8,077 ver-
sus  €2,756) and 4.7 fold (€12,939 versus €2,756)
increase, respectively [3]. Epidemiological surveys of rep-
resentative patient groups in Germany have shown that
many diabetes patients fail to achieve adequate glycaemic
control (HbA1c = 6.5%) and almost half of all patients
have at least one diabetes-related complication [1,3,5-7].
In the CoDiM study, 41% of the 11,983 patient treated
with oral antidiabetic (OAD) agents alone reportedly had
macrovascular disease, and the corresponding values were
52% and 44% for patients treated with OAD plus insulin
or diet alone respectively [3]. In the earlier CODE-2 study
50% of the type 2 diabetes patients had at least one com-
plication [1]. More recently the Diabetes Cardiovascular
Risk Evaluation: Targets and Essential Data for Commit-
ment of Treatment (DETECT) Germany-wide study con-
ducted in 2003 and including 8,188 type 2 diabetes
patients reported that 50% of patients had at least one dia-
betes complication and 34% had macrovascular compli-
cations [6]. Therefore, there exists a clear need from both
a clinical and economic view for more effective interven-
tion among these patients at increased risk for further
complications and for progressive worsening of estab-
lished complications.
The thiazolidinedione (TZD) class of anti-hyperglycaemic
agents act via stimulation of the peroxisome proliferator
activated receptor-γ (PPAR-γ) to increase sensitivity to
insulin in muscle, liver and adipose tissue and thereby
improve glycaemic control [8,9]. The TZD, pioglitazone,
has been shown in randomized clinical trials to signifi-
cantly lower blood glucose and to improve lipid abnor-
malities in patients with type 2 diabetes when used as
monotherapy or in combination with other oral antihy-
perglycaemic agents or insulin [10-13]. In addition to this,
and in contrast to metformin and sulphonylureas (SU),
recent studies have provided evidence of pioglitazone
associated improvement in pancreatic β-cell function that
correlates strongly with improved glycaemic control in
patients with type 2 diabetes [14]. The European Medi-
cines Agency (EMEA) has recently extended the approved
indications for pioglitazone to include use in combina-
tion with insulin for patients with insufficient control on
insulin and a contraindication or intolerance for met-
formin. Pioglitazone is also indicated for use as mono-
therapy in patients inadequately controlled with diet and
exercise and for whom metformin is contraindicated; as
dual oral therapy in combination with metformin or SU
for patients with inadequate control and SU or metformin
intolerance respectively; as triple oral therapy in combina-
tion with metformin and a SU for patients failing to
achieve adequate control with dual oral therapy [15].
Of particular relevance to the needs of type 2 diabetes
patients in Germany, the PROspective pioglitAzone Clin-
ical Trial in macroVascular Events (PROactive) investi-
gated prospectively the effect of pioglitazone, used as an
"add on" to normal treatment regimens, on macrovascu-
lar outcomes in patients with a history of macrovascular
events and demonstrated that treatment was associated
with a reduced incidence of cardiovascular events [16,17].
The PROactive study was conducted in 321 centres in 19
European countries and recruited 5,238 type 2 diabetes
patients who were followed up for an average of 34
months. At the end of study, there was a 10% relative risk
reduction with pioglitazone in the primary endpoint (p =
0.09, non-significant), which was a composite of all cause
mortality, non-fatal myocardial infarction (MI) (includ-
ing silent MI), stroke, acute coronary syndrome (ACS),
endovascular or surgical intervention in the coronary or
leg arteries, and amputation above the ankle. For the prin-
cipal secondary composite endpoint (all cause mortality,
MI or stroke) treatment with pioglitazone was associated
with a significant reduction compared to placebo (hazard
ratio = 0.84, p = 0.027). By the end of PROactive, patients
receiving pioglitazone reported significant improvements
in HbA1c, high-density lipoprotein (HDL) cholesterolCost Effectiveness and Resource Allocation 2009, 7:9 http://www.resource-allocation.com/content/7/1/9
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and triglycerides compared to those receiving placebo
[17]. In the PROactive study, pioglitazone reduced the
number of patients progressing to long-term insulin ther-
apy by half. In addition to this, evidence supporting the
potential of TZDs to stabilize pancreatic function and
hence glycaemic control continues to accumulate, with a
number of reports based on clinical observations in type
2 diabetes patients now supporting earlier evidence
gained in animal models [14,18].
These findings demonstrate that improved glycaemic and
lipid control associated with pioglitazone treatment lead
to a reduced incidence of macrovascular events and in
contrast to most currently available treatment options use
of pioglitazone could potentially delay the progressive
decline of pancreatic function that undermines attempts
to achieve adequate glycaemic control. In view of the sub-
stantial burden imposed by diabetes-related complica-
tions on German healthcare resources, uptake of
pioglitazone by patients at high risk for complications or
progression of existing complications may represent an
important treatment option in both clinical and eco-
nomic terms. However as increasing demands are being
placed on limited healthcare resources there is a need to
demonstrate that treatments are both effective in clinical
terms and affordable in economic terms if they are to be
made available to those most likely to benefit. The objec-
tive of this study was to estimate the impact of pioglita-
zone treatment on life expectancy, quality-adjusted life
expectancy and incidence of macrovascular events and to
account for direct medical costs over a patient lifetime
horizon in the German setting.
Methods
Model
Short-term clinical effects of the pioglitazone and placebo
treatment regimens from PROactive were used to project
long-term outcomes using a modified version of the
extensively published and validated CORE Diabetes
Model [19,20].
The CORE Diabetes Model is a computer simulation
model developed to determine the long-term health out-
comes and economic consequences of interventions in
diabetes. Disease progression is modelled via 15 inter-
dependent semi-Markov sub-models that simulate pro-
gression of disease related complications (angina, MI,
congestive heart failure, stroke, peripheral vascular dis-
ease, diabetic retinopathy, macula oedema, cataract,
hypoglycaemia, ketoacidosis, lactic acidosis, nephropathy
and end-stage renal disease, neuropathy, foot ulcer,
amputation and non-specific mortality). Each sub-model
uses time, state and diabetes type-dependent probabilities
derived from published sources. Using the CORE Diabe-
tes Model diabetes management strategies can be com-
pared in different patient populations in a variety of
realistic clinical and economic settings.
In the current study, short-term (0 – 3 years) data from
PROactive was used as a basis for long-term projections
using the CORE Diabetes Model adapted to include clini-
cal input data from PROactive [21]. For a more detailed
account of the PROactive long-term simulation model
describing the adaptation of the original CORE Diabetes
Model, the transition probabilities applied and the utility
values accounted for disease states interested readers are
encouraged to view the publication of Valentine et al.
[21].
In brief, to incorporate the PROactive clinical and adverse
event endpoint data into the CORE Diabetes Model, a
number of new complication sub-models were developed
or modified. The overall architecture of the modified
CORE Diabetes Model remained analogous to the origi-
nal version, with all active sub-models running in parallel
to simulate the progression of disease and the develop-
ment of diabetes-related complications. The sub-models
included in the final PROactive long-term simulation
model were; acute coronary syndrome, percutaneous cor-
onary intervention (PCI), coronary artery bypass graft
(CABG), bypass surgery/revascularization of the leg, hos-
pital admission for heart failure, non-serious heart failure,
oedema, myocardial infarction, transient ischemic attack
(TIA), stroke, photocoagulation, severe vision loss, neph-
ropathy, peripheral vascular disease, diabetic foot, ampu-
tation, and cataract (Figure 1).
Event rates in the placebo arm were calculated directly
from the annual hazard rates observed over months 0–36
of PROactive assuming constant risk [21]. To calculate
event rates in the pioglitazone arm hazard ratios were
applied to the event rates from the placebo arm in line
with the relative risk observed for each event during
PROactive. To capture the statistical uncertainty in the
trial data, hazard ratios in the modelling simulations were
randomly sampled from a lognormal distribution gener-
ated from μ and σ values derived directly from the trial
data. Constant risk was assumed for application of hazard
ratios to calculate event rates in the pioglitazone arm for
all endpoints with the exception of oedema, where hazard
ratios were sampled from separate distributions for the
first and subsequent years of the simulation to capture the
decrease in risk after the first year of treatment with piogl-
itazone (see Additional file 1).
All-cause and cardiovascular mortality rates were derived
directly from the PROactive Study for years 1–3 of the
simulation, with rates subsequently doubling every 10
years [22]. Event rates for following years were calculated
by applying relative risk adjustments from the UnitedCost Effectiveness and Resource Allocation 2009, 7:9 http://www.resource-allocation.com/content/7/1/9
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Kingdom Prospective Diabetes Study (UKPDS) and Fram-
ingham data for each additional life-year gained (i.e. as
the patient gets older, his/her risk of experiencing an event
increases) [23-27]. In all sub-models, the occurrence of
events resulted in the accounting of event costs and, where
applicable, subsequent state costs as well as assignment of
the appropriate disutility values.
The modified CORE Diabetes Model estimated the impact
of treatment on life expectancy, quality-adjusted life
expectancy (based on CODE-2 utilities), diabetes-related
complications (cumulative event rates), direct medical
costs and cost-effectiveness ratios over patient lifetimes, in
line with specifications for health economic evaluations
and under the assumption that treatment allocation con-
tinues [28,29].
Simulation Cohorts
A simulation cohort of patients was defined with baseline
demographics, and complications representative of the
two treatment arms from PROactive. Long-term outcomes
were calculated 1,000 times in the model using a simu-
lated population of 1,000 patients, in order to capture the
effects of random variation between individual patients.
At baseline the simulation cohort had a mean age of 61.8
years, duration of diabetes 10 years, and a mean HbA1c
level of 8.1% (Table 1). For the purposes of this analysis
patients were assumed to remain on the same treatment
regimen for the duration of the simulation (35 years or
death).
The use of angiotensin converting enzyme inhibitors
(ACE inhibitors) has an important influence on renal out-
comes and in the simulation cohort this was set to 62.8%
based on data from PROactive. Use of aspirin and statin
medication has an impact on cardiovascular events, and
in line with the PROactive study cohort 73.1% and 42.9%
of the simulation cohort were assigned to receive these
treatments respectively. Therefore, risk adjustment for the
use of aspirins or statins was disabled in the analysis as the
influence of these agents was already taken into account,
along with the impact of ACE inhibitors, in the cardiovas-
cular event rates taken from PROactive. It is relevant to
note here that a survey of prescription drug costs for dia-
betic patients in Germany reported that approximately
45% of patients with type 2 diabetes were treated with
ACE inhibitors and 25% with statins in 2004 [30]. Addi-
tional settings for patient management parameters (e.g.
screening for renal disease) were set in line with the stand-
ard of care patients in the PROactive study were receiving,
with all patients receiving regular screening and foot
check-ups.
Treatment effects
For the base case simulation, the clinical effects associated
with the pioglitazone and placebo treatment regimens
were applied as observed during PROactive. Treatment
effects on HbA1c were applied separately in simulation
years 1, 2 and 3, and in subsequent years, based on the
findings from PROactive (for long-term projection).
Changes in HbA1c and other parameters for pioglitazone
and placebo regimens were applied as summarized in
Table 2 and based on the statistical report compiled by
Nottingham Clinical Research Limited for the PROactive
study group. After year three of PROactive the between
treatment group difference in HbA1c was -0.5% for piogl-
itazone versus placebo. The long-term progression of all
of these clinical parameters subsequently followed the
patterns previously described by Palmer et al. in their
description of the CORE Diabetes Model [19].
Costs
Direct medical costs were expressed in 2005 Euro (€) and
taken from Germany specific sources where possible
(Table 3). Unit costs retrieved from published sources that
were not expressed in 2005 € values were inflated using
indices from the German Federal Statistics Office http://
www.destatis.de. Direct medical costs were calculated as
the sum of treatment costs (based on data from PROac-
tive), patient management costs and the cost of complica-
tions. The annual costs of study medication were
accounted based on data from PROactive and a mean
annual cost of €736.15 per patient for pioglitazone and
zero for placebo. Calculations were based on daily costs of
€1.29, €1.93 and €2.31 for treatment with 15 mg, 30 mg
and 45 mg pioglitazone and zero cost for placebo.
Health state utilities
For the base case analysis, health state utilities for the
events reported in PROactive were derived wherever pos-
Overview of the PROactive long-term simulation model Figure 1
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sible from the CODE-2 study [31]. Where PROactive
events were not taken into consideration in the CODE-2
formula, no substitute values were used (as this could
have produced erroneous findings). All other quality of
life utilities used in the base case simulation have been
described previously by Palmer et al. [19]. Sensitivity anal-
yses were performed to investigate the impact of including
additional quality of life disutilities on the base case find-
ings. A list of all PROactive model specific utilities incor-
porated into the model is given in Additional file 2.
Discounting, Time Horizon and Perspective
Discounting was applied to costs, life expectancy and
quality-adjusted life expectancy at an annual rate of 5.0%
in line with current recommendations for the German set-
ting [32]. To capture all relevant long-term complications,
a lifetime horizon of 35 years was used in the analysis. The
analysis was conducted from a third-party healthcare
payer perspective in Germany.
Sensitivity Analyses
Sensitivity analyses were performed to investigate the
impact of key input variables on the projected outcomes
of the analysis. Typically these were univariate sensitivity
analyses where the base case parameters were left
unchanged except for the parameters specifically called
out in the descriptions here. In the base case, changes in
HbA1c were simulated using data from PROactive in the
first three years and thereafter (years 4+) an annual
increase in HbA1c of 0.15% was assumed in line with
observations from UKPDS [33]. To investigate the impact
of potential benefits with respect to β-cell function a sen-
sitivity analysis was performed where the annual HbA1c
creep of 0.15% was reduced to 0.1% for years 4+. There
were very few hypoglycaemic events observed in the
PROactive trial but to investigate the potential impact of
these on the overall outcomes a sensitivity analysis was
performed where all events were associated with a cost of
€2,555 in line with data from Holstein et al. [34]. The
impact of time horizon was investigated by varying this
between 10 and 35 years. Similarly, the impact of dis-
count rates was assessed by varying this between zero and
10% in line with recommendations of the Hanover con-
sensus [29]. Treatment related assumptions were investi-
Table 1: Baseline characteristics of the simulation cohort
Characteristic Value SD Data Source
Demographics
Proportion male (%) 66.1 -- PROactive
Mean age (years) 61.8 7.7 PROactive
Duration of diabetes (years) 10 7 PROactive
Ethnic Group
Proportion White (%) 98.6 -- PROactive
Proportion Black (%) 1.4 -- PROactive
Baseline risk factors
HbA1c (%-points) 8.1 1.4 PROactive
Systolic blood pressure (mmHg) 143.4 17.8 PROactive
BMI (kg.m-2) 30.9 4.8 PROactive
HDL-C (mmol/l) 1.2 0.3 PROactive
LDL-C (mmol/l) 3.0 1.0 PROactive
Total cholesterol (mmol/l) 2.3 0.9 PROactive
Triglycerides (mmol/l) 2.2 1.8 PROactive
Proportion smokers (%) 13.8 -- PROactive
Baseline complications
ACS (%) 13.65 -- PROactive
CABG/PCI (%) 30.75 -- PROactive
PVD (%) 24.3 -- PROactive
MI (%) 47.0 -- PROactive
Stroke (%) 19.0 -- PROactive
Microalbuminuria (%) 14.3 -- PROactive
Neuropathy (%) 25.6 -- PROactive
HbA1c = glycosylated haemoglobin; BMI = body mass index; HDL-C 
= high density lipoprotein cholesterol; LDL-C = low density 
lipoprotein cholesterol; ACS = acute coronary syndrome; CABG = 
coronary artery bypass graft; PCI = percutaneous coronary 
intervention; MI = myocardial infarction
Table 2: Summary of base case intervention effects
Effect Mean change from baseline
Pioglitazone Placebo
Change in HbA1c in year 1 (%-points) -0.9 -0.3
Change in HbA1c in year 2 (%-points) +0.1 +0.1
Change in HbA1c in year 3 (%-points) +0.3 +0.2
Change in subsequent years +0.15 +0.15
Total cholesterol (mmol/l) +0.39 +0.25
HDL-C (mmol/l) +0.54 +0.30
LDL-C (mmol/l) +0.35 +0.22
Triglycerides (mmol/l) -0.064 +0.076
Systolic blood pressure (mmHg) -3.8 -2.4
BMI (kg.m-2) +1.1 -0.1
Overall hypoglycaemic event rate (per 100 patient years)* +9.29 +6.68
HDL-C = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol; BMI = body mass index.
* Includes both minor events not requiring assistance [726 patients on pioglitazone and 528 on placebo, (p < 0.0001)] and major events that 
resulted in admission to hospital [19 patients on pioglitazone and 11 patients on placebo (p = 0.14)].Cost Effectiveness and Resource Allocation 2009, 7:9 http://www.resource-allocation.com/content/7/1/9
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gated by varying the impact of pioglitazone treatment on
HbA1c such that both pioglitazone and placebo arms sim-
ulated a change in HbA1c of -0.3% corresponding to the
PROactive placebo arm. The influence of risk adjustment
for age on the event rates taken from PROactive was inves-
tigated by performing an analysis where no risk adjust-
ment for age was applied during the simulation (risk
adjustment factors all set to 1). In order to examine the
effect of uncertainty on costs accounted in the model, sen-
sitivity analyses were conducted varying the unit cost of
pioglitazone treatment by +/- 20% and then also by vary-
ing all other costs (complication and management) by the
same margins.
In the base case scenario quality of life utilities were taken
from CODE-2, and for many events such as oedema and
heart failure this resulted in no disutilities being applied
due to the absence of data. To investigate the influence of
including quality of life disutilities not included in the
CODE-2 formula a number of sensitivity analyses were
run to include additional quality of life disutilities as pre-
viously described [21]. In brief, this involved repeating
the base case analysis using the CORE default method of
quality-adjusted life expectancy estimation, applying an
event disutility of -0.01 for oedema and a follow up disu-
tility of zero (as the condition is typically short-lived),
applying an event disutility to hospitalization for heart
failure of -0.121 and a follow up disutility of -0.181, based
on the UKPDS [35], or applying an event disutility of -
0.0605 for non-serious heart failure and a follow up disu-
tility of zero (due to the absence of published data). Util-
ity values for oedema and non-serious heart failure were
based on assumptions.
A "worst case" scenario was also included in the sensitivity
analysis where event disutilities for oedema (as
described), hospitalization for heart failure (by applying
an event disutility of -0.121 and a follow up disutility of -
0.181) and revascularization of the leg (by applying an
event disutility of -0.059 and a follow up disutility of zero,
assuming a disutility comparable to that reported for
CABG) from the post-hoc study of Lescol Intervention
Prevention Study were applied [36].
Statistical Methodology
The health economic analysis was performed using a non-
parametric bootstrapping approach in which the progres-
sion of diabetes was simulated in 1,000 patients through
the model 1,000 times to calculate the mean and standard
deviation of costs, life expectancy and quality-adjusted life
Table 3: Cost per event or state used in the analysis, expressed in 2005 values (€)
Event cost (€) Follow up cost (€) Reference(s)
Death (all causes) 0.00 0.00 Assumed
CVD death 0.00 0.00 Assumed to be zero as no published value was found
MI (excluding silent MI) 8,634.93 3,647,32 [49]
Silent MI 0.00 0.00 Assumed
Acute coronary syndrome (ACS) 3,120.92 0.00 [50]
CABG only 12,435.81 0.00 [51]
PCI only 4,360.03 0.00 [51]
Stroke 10,523.62 6,178.06 [49] and [52]
Leg amputation (major, above ankle) 15,405.10 3,303.92 [49] and [53]
Bypass surgery/revascularization of leg 6,268.09 0.00 [50]
Transient ischemic attack (TIA) 2,353.52 0.00 [50]
Retinal photocoagulation 1,862.28 340.33 [50]
Severe vision loss (SVL) 10,660.98 10,660.98 [54]
Hospitalization for CHF 2,272.97 0.00 [55]
Non-serious heart failure 34.51 0.00 Assumed to be same as a physician visit cost 
(as CVD medication costs are already captured)
Oedema 34.51 0.00 [56]
Peripheral vascular disease (onset) 2,635.85 0.00 [56]
Haemodialysis 59,248.85 59,248.85 [57]
Peritoneal dialysis 47,198.66 47,198.66 [57]
Kidney transplant 69,504.00 11,116.77 [58]
Cataract extraction 1,347.78 0.00 [59]
Neuropathy, onset 3,930.36 0.00 [60]
Uninfected ulcer 894.22 0.00 [60]
Infected ulcer 1,818.58 0.00 [60]
Gangrene 3,247.62 0.00 [60]
Major hypoglycaemic event 2,555 0.00 [34]
CVD = cardiovascular disease; MI = myocardial infarction; CABG = coronary artery bypass graft; PCI = percutaneous coronary intervention; CHF 
= congestive heart failure. Where necessary costs were inflated to 2005 valuesCost Effectiveness and Resource Allocation 2009, 7:9 http://www.resource-allocation.com/content/7/1/9
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expectancy using second order Monte Carlo simulation
[37]. Mean results from each of the 1,000 iterations were
used to create a scatter plot, comparing the differences in
costs and outcomes for pioglitazone and placebo treat-
ment regimens. These values were in turn used to generate
a cost-effectiveness acceptability curve over a range of will-
ingness to pay values in the German setting.
Results
Life expectancy and quality-adjusted life expectancy
The current health-economic analysis indicated that based
on clinical findings for PROactive and long-term projec-
tions with a modified version of the CORE Diabetes
Model, treatment with pioglitazone was associated with
improvements in life expectancy and quality-adjusted life
expectancy compared to placebo. Mean life expectancy
(discounted by 5.0% per annum) increased by 0.172 years
with pioglitazone and after adjustment for quality of life
an improvement of 0.120 quality-adjusted life years
(QALYs) was projected versus placebo (Table 4). When no
discounting was applied to the long-term outcomes,
mean life expectancy in the pioglitazone treatment arm
was 0.406 years longer than in the placebo arm.
Lifetime costs and cost-effectiveness
Over patient lifetimes, treatment with pioglitazone was
associated with higher direct medical costs than the pla-
cebo regimen (Table 4). Direct costs increased by €1,599
with pioglitazone compared to placebo. This increase was
largely due to increased treatment costs (€27,210 versus
€24,348), whilst complication-related costs decreased by
€1,263 (Table 5). Treatment with pioglitazone was asso-
ciated with a reduced cost for stroke events by €1,487 and
an increase in costs by €274 for hospitalization for heart
failure compared to placebo (although mortality rates
from heart failure did not differ between groups).
Estimation of incremental cost-effectiveness ratios (ICER)
for pioglitazone versus placebo treatment produced val-
ues of €9,281 per life year gained and, taking quality of
life into account, €13,294 per QALY gained (Table 4). The
values from the 1,000 means (each from 1,000 patients)
of incremental costs and incremental effectiveness (in
terms of quality-adjusted life expectancy) were used to
generate a scatter plot on the cost-effectiveness plane. This
analysis shows that the majority of points were in the
upper right quadrant of the plane, indicating increased
effectiveness and increased costs associated with pioglita-
zone treatment over placebo. These values were then used
to create a cost-effectiveness acceptability curve by assess-
ing what proportion of values fell below set willingness to
pay values (Figure 2). The analysis demonstrated that,
with a willingness to pay of €50,000 per QALY in the Ger-
man setting, there was a high probability (78.2%) that
pioglitazone would be cost-effective (Figure 3).
Sensitivity Analyses
Sensitivity analysis showed that the results were most sen-
sitive to variation in the time horizon and assumptions on
the duration of the benefits of pioglitazone treatment
observed in the trial, whilst the exclusion of improved β-
cell function from the base case scenario was shown to
bias against pioglitazone (see Additional file 3).
To simulate a pioglitazone-associated delay in β-cell dete-
rioration the annual HbA1c creep was reduced from
0.15% to 0.10%, over a 35-year time horizon the pro-
jected quality-adjusted life expectancy improved and
direct costs were reduced such that pioglitazone became
dominant compared to the base case value of €13,294 per
QALY gained, this was primarily due to pioglitazone
being less costly (€102,954 versus €103,834). In the sce-
nario where the cost for any hypoglycaemic event was set
at  €2,555 the ICER increased slightly to €13,980 for
pioglitazone versus placebo. Reducing the time horizon to
ten years (compared to the base case of 35 years)
increased the ICER compared to the base case. This occurs
because shorter time horizons fail to capture the develop-
ment of many end-stage complications, such as end-stage
renal disease, severe vision loss and macrovascular com-
plications, some of which would be avoided in the piogl-
itazone treatment group. A time horizon of 20 years was
associated with a moderately improved ICER compared to
the base case (€10,144 per QALY gained). This outcome
is most likely due to the increased life expectancy of
patients receiving pioglitazone compared to placebo, such
that beyond 20 years there are more surviving patients
and hence they accumulate greater costs.
Addition of various disutility values for inclusion in the
analysis had very little effect on the relative findings of the
analysis with ICERs remaining well below the willingness-
to-pay threshold of €50,000 per QALY gained. Assuming
no difference between treatments in HbA1c change also
had very little impact on outcomes, and this was in line
with the modest between treatment group difference in
HbA1c from year 4+ and the cohort HbA1c of 8.1% at
baseline. Nevertheless, the improved cardiovascular risk
profile associated with pioglitazone meant that direct
costs were reduced (€1,412 versus €1,599), which in turn
meant that the ICER was lower than in the base case;
€11,870 per QALY gained for pioglitazone versus pla-
cebo.
By reducing the unit cost of pioglitazone by 20%, from
€736.15 to €588.92, resulted in a lower ICER of €424 per
QALY gained for pioglitazone versus placebo. Further-
more increasing the cost of pioglitazone by 20% to
€883.38 resulted in an ICER of €26,162 per QALY gained.
When altering all other costs inputs in the model by +/-
20% the incremental costs and corresponding ICERs forCost Effectiveness and Resource Allocation 2009, 7:9 http://www.resource-allocation.com/content/7/1/9
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pioglitazone versus placebo were €1,447 and €12,035 for
a reduction in costs of 20% and €1,750 and €14,553 for
an increase in costs of 20%, respectively.
Discussion
Based on outcomes from PROactive the addition of piogl-
itazone to current treatment regimens would be associ-
ated with an ICER of €13,294 per QALY gained when
viewed over a lifetime time horizon in the German setting.
In the base case analysis, treatment with pioglitazone was
associated with improvements in life expectancy of 0.172
years and quality-adjusted life expectancy of 0.120
QALYs, and slightly higher direct medical costs (€1,599)
over patient lifetimes.
Results from both the German arm of the CODE-2 and
the more recent German CoDiM study identified treat-
ment of complications as the main driver of direct costs
[1,3,4,38]. Meanwhile three very large epidemiological
surveys conducted in 2001 and 2003 indicate that 33–
50% of currently diagnosed type 2 diabetes patients in
Germany have a history of macrovascular events and
approximately 50% have inadequate glycaemic control
[3,6]. Therefore the European cohort of patients with a
history of macrovascular events included in PROactive
and hence the outcomes reported from PROactive, are
highly relevant to many type 2 diabetes patients currently
cared for in the German setting. Treatment with pioglita-
zone lowers blood glucose and improves lipid abnormal-
ities. For patients at high risk for macrovascular events,
epidemiological studies such as the UKPDS have clearly
demonstrated that multifactorial intervention to improve
blood pressure and lipids as well as glycaemic control is
likely to have a greater impact on the occurrence of future
events than relying solely on improvement in HbA1c [39].
It is to be noted that the UKPDS recruited newly diag-
nosed patients as opposed to established patients.
In addition to providing evidence that improved glycae-
mic control reduces the incidence of complications, the
UKPDS also demonstrated the progressive deterioration
of glycaemic control despite use of antidiabetic medica-
tion. This occurs primarily as a consequence of declining
pancreatic β-cell function, however most currently availa-
ble treatment options for diabetes do not address this
underlying cause of deteriorating control in diabetes. In
contrast, use of the orally available pioglitazone is associ-
ated with improved glycaemic control via its insulin-sen-
Table 4: Summary of base case results for pioglitazone versus placebo
Outcome (all reported values are discounted) Pioglitazone Placebo Difference (PIO – PLA)
Clinical outcomes
Life expectancy (years) 10.044 (0.140) 9.871 (0.139) 0.172
Quality-adjusted life expectancy (QALYs) 7.543 (0.102) 7.422 (0.102) 0.120
Cost outcomes
Total direct costs (€) 105,433 (2,650) 103,834 (2,618) 1,599
Incremental cost-effectiveness based on life expectancy €9,281 per life year gained
Incremental cost-effectiveness based on quality-adjusted life 
expectancy
€13,294 per QALY gained
Values shown are means with standard deviation in parentheses; PIO = pioglitazone; PLA = placebo; QALY = quality-adjusted life-years. Incremental 
values are given as the pioglitazone value minus the placebo value.
Table 5: Breakdown of direct costs for pioglitazone versus placebo over a lifetime horizon
Cost (per patient) Pioglitazone (€)P l a c e b o  ( €) Difference (PIO – PLA) (€)
Treatment 22,941 20,151 2,790
Management 4,269 4,197 72
Total complication costs 78,223 79,486 -1,263
Total direct costs 105,433 103,834 1,599
Total direct medical costs were estimated as the sum of pharmacy costs based on resource use from PROactive, patient management costs 
(screening for retinopathy, nephropathy and foot ulcers), and the costs of all diabetes-related complications captured in the analysis. Values shown 
are means.Cost Effectiveness and Resource Allocation 2009, 7:9 http://www.resource-allocation.com/content/7/1/9
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sitizing effects and has the potential to stabilize pancreatic
function and hence stabilize glycaemic control [14,40].
Adjustment of the current analysis to take this into consid-
eration further improved the cost-effectiveness of pioglita-
zone versus placebo, resulting in an ICER of €6,667 per
QALY gained.
As noted in a recent review of the cost of diabetes in Ger-
many by Liebl, the reporting of outcomes in terms of
patient benefits including duration and quality of life are
of particular importance in formulating healthcare policy
[1]. Therefore it was important to perform appropriate
sensitivity analyses to explore the robustness of projected
outcomes to changes in the quality of life utilities
assumed in the current analysis.
Although the quality of life utilities reported from CODE-
2 were specific for European patients with type 2 diabetes
the utilities were based on 4,641 study participants from
Belgium, Italy, Netherlands, Spain and Sweden, and
therefore a potential weakness of the current study is that
these may not be representative of attitudes among Ger-
man patients. The lack of Germany specific quality of life
data was recently highlighted in a review of German eco-
nomic evaluations of healthcare [41]. Until newer studies
are conducted and published, the use of quality of life
data taken from European patients with type 2 diabetes as
utilized in the present investigation currently constitutes
the best evidence available regarding likely preferences of
German type 2 diabetes patients.
In addition to this a second potential weakness of the
analysis presented here, in terms of quality of life, was the
conservative approach taken to the estimation of quality-
adjusted life expectancy using only data from CODE-2.
This estimation did not capture changes in quality of life
associated with several macrovascular endpoints (MI,
ACS, PCI, CABG, TIA, oedema or revascularization of the
leg). It is possible that this methodology may underesti-
mate the improvements in quality-adjusted life expect-
ancy as the formula does not capture some of the benefits
of pioglitazone treatment (reduced rates of MI, ACS, PCI
and CABG) or certain disadvantages such as oedema
(although this was partially captured by the inclusion of
body mass index [BMI] disutility data), hospitalization for
heart failure and revascularization of the leg. This was
addressed in the sensitivity analysis by including quality
of life disutilities related to these endpoints and resulted
in ICERs that were higher than projected in the base case
(range €13,660–24,807 per QALY gained versus base case
€13,294 per QALY gained). However it should be noted
that this approach did not take into consideration poten-
tial improvements in quality of life resulting from
decreased macrovascular events, and therefore is likely to
bias against pioglitazone treatment.
As with all economic evaluations cost the accounting of
costs is a potential area of weakness and should be ade-
quately investigated for it's effect on outcomes. Sensitivity
analyses have been performed to this end by varying cost
inputs by +/- 20% and the resultant outcomes have been
shown to be largely unchanged. It should also be noted
that some cost inputs used in the analysis are ten years old
and although this is not ideal, in the absence of any other
data these are likely to provide better cost estimates than
other commonly used options (e.g. anecdotal estimates
from clinicians), even when inflated to current values
using composite price indices.
Although the model bases outcomes primarily on the
results of PROactive which was designed to report mac-
rovascular endpoints, the model also captures other com-
plications previously projected by the CORE Diabetes
Model (nephropathy, neuropathy, peripheral vascular
disease, foot ulcers and cataract). These sub-models use
published data to account the risk of onset and progres-
sion and it should be acknowledged that these risks may
differ for the patient population from PROactive. This
uncertainty is unavoidable when constructing a non-trial
based model but the errors are reduced somewhat by per-
forming comparative analyses where inherent errors are
applied to both interventions being compared.
Cost-effectiveness acceptability curve analysis indicated
that there would be a 78.2% likelihood that pioglitazone
would be cost-effective with a willingness to pay threshold
of €50,000 per QALY gained. Although this threshold is
frequently cited in health economic evaluations, very few
countries or healthcare authorities have set an explicit
Cost-effectiveness scatter plot of incremental costs and  incremental effectiveness for pioglitazone versus placebo Figure 2
Cost-effectiveness scatter plot of incremental costs 
and incremental effectiveness for pioglitazone versus 
placebo.
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threshold [42]. One exception to this is the Dutch Council
for Public Health and Health Care who, in 2006, advised
the government to set an explicit limit of €80,000 per
QALY gained for diseases or injuries with a burden of 1.0
(causing a complete loss of all otherwise remaining
QALYs) when making reimbursement decisions [43]. Fur-
ther reporting of these recommendations indicated that
for a burden of 0.5 the maximum threshold would be
€40,000 under the recommendations of the Dutch Coun-
cil [44]. Although a threshold range of £20,000–£30,000
per QALY gained has frequently been cited for the UK set-
ting an explicit threshold has not been defined by the
National Institute for Health and Clinical Excellence
(NICE) [45-47]. In their detailed analysis of 33 economic
evaluations previously brought before NICE, Devlin and
Parkin noted an upper threshold of £47,000–£50,000 per
life year gained for the UK setting [45]. In view of these
apparent or likely thresholds for other European countries
the threshold of €50,000 would seem to represent a rea-
sonable assumption in the absence of explicit thresholds
for Germany.
A recent commentary on the implications of PROactive in
clinical practice showed that for treatment with pioglita-
zone the number needed to treat (NNT) to prevent either
the combined primary or combined secondary cardiovas-
cular endpoint (NNT 50 and 49 respectively) was well
within the range reported for studies investigating the use
of statins or ACE inhibitors for the prevention of cardio-
vascular events [48]. The current investigation has shown
that based on use of a model that specifically incorporates
outcome data (both for hard endpoints and adverse
events) from the same trial that cohort characteristics and
treatment effects were taken, pioglitazone represents a
cost-effective treatment option in the German setting. In
view of these outcomes, pioglitazone represents a valid
treatment option for patients with a history of macrovas-
cular events both in clinical and economic terms. It will be
of interest in the future to assess the cost-effectiveness of
pioglitazone for the remaining (approximately 50%) Ger-
man type 2 diabetes patients without macrovascular dis-
ease who are likely to benefit from improved glycaemic
control and the potential stabilization of pancreatic cell
function prior to the development of costly diabetes-
related complications.
Conclusion
Based on outcomes from PROactive this modelling study
demonstrates that the addition of pioglitazone to current
treatment regimens in the German setting is likely to be
viewed as good value for money over patient lifetimes.
There were benefits in terms of both projected life expect-
ancy and quality-adjusted life expectancy accompanied by
cost savings from complications avoided and increased
treatment and overall total lifetime costs.
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